These guys correctly predicted why Afrezza is superior to BIOD insulin's. You can see their 18 June Mannkind update for analysis and conclusion. Latest update is dated in August after phase 3 trials. The analyst has background in biotechnology and holds PhD plus MBA.
Can't find the price target, all I can find "Keith Markey of Griffin Securities feels that MannKind has managed to clear a significant inflection point and has enough financing to get through the approval process"
This is a great find and thank you for reminding us of it. Interesting how that stupid, under-researched and clearly flawed (if not fraudulent) report by that BofA looser captured all the headlights and this has been buried in the sand.
You guys don't really get it at all do you. It wasn't the downgrade that made people sell in premarket. They HF felt with all the stops in place that a bear raid would be successful so they pay a lackey to say what they want people to believe which also supports the sell off and walla, you have Friday's activities. Once the stops were taken out, what happened. The stock rebounded and stayed flat the rest of the day. Sign that selling was over and order was restored. No one cares about the B of A and what they say of think. There are a terrible bank (1st hand experience) and an even worst analyst.